Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CASI
stocks logo

CASI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2026Q1
0.00
-100%
-0.400
-27.27%
0.00
-100%
-0.370
-46.38%
Estimates Revision
The market is revising No Change the revenue expectations for CASI Pharmaceuticals, Inc. (CASI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -58.19%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-58.19%
In Past 3 Month
Wall Street analysts forecast CASI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CASI is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CASI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CASI is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.978
sliders
Low
4.00
Averages
4.00
High
4.00
Current: 0.978
sliders
Low
4.00
Averages
4.00
High
4.00
HC Wainwright & Co.
Sean Lee
Strong Buy
Maintains
$6 → $4
2025-04-09
Reason
HC Wainwright & Co.
Sean Lee
Price Target
$6 → $4
2025-04-09
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for CASI Pharmaceuticals Inc (CASI.O) is -0.67, compared to its 5-year average forward P/E of -3.60. For a more detailed relative valuation and DCF analysis to assess CASI Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.60
Current PE
-0.67
Overvalued PE
0.38
Undervalued PE
-7.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.63
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.71
Undervalued EV/EBITDA
-4.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.90
Current PS
0.00
Overvalued PS
6.40
Undervalued PS
-0.59
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

CASI News & Events

Events Timeline

(ET)
2025-09-26
09:52:52
Casi Pharmaceuticals names James Hunag to its board of directors
select
2025-09-08 (ET)
2025-09-08
09:22:58
CASI recommends increasing CID-103 dosage for the next cohort, according to announcement.
select
2025-09-02 (ET)
2025-09-02
09:06:03
Casi Pharmaceuticals names Barbara Krebs-Pohl to its board of directors
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
08-18Benzinga
Dayforce Shares Surge Approximately 21%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Dayforce Inc Acquisition Talks: Shares of Dayforce Inc rose 21.4% in pre-market trading following reports that Thoma Bravo is in discussions to acquire the company.

  • Notable Gainers: Other stocks experiencing significant gains include Propanc Biopharma (up 253%), Adaptimmune Therapeutics (up 70.3%), and DIH Holding US (up 43.4%).

  • Significant Losers: TPI Composites saw a drastic decline of 51.1%, while SRx Health Solutions and Empery Digital also faced notable drops of 25.8% and 22.2%, respectively.

  • Market Overview: The article highlights various stocks' movements in pre-market trading, showcasing both substantial gainers and losers, reflecting market volatility.

[object Object]
Preview
2.0
08-18NASDAQ.COM
Premarket Stock Movements: PPCB, BTAI, TNXP, DAY, TPIC, and Other Notable Gainers and Losers

  • Premarket Trading Activity: Notable activity is observed in premarket trading as of 6.50 a.m. ET on Monday, indicating potential opportunities before the market opens.

  • Importance for Traders: Premarket trading allows active traders to identify possible breakouts, reversals, or price swings, making it crucial for analyzing momentum heading into the regular session.

  • Stocks Performance: Some stocks are showing significant percentage increases while others are experiencing notable declines during Monday's premarket session.

  • Author's Perspective: The views expressed in the article reflect the author's opinions and do not necessarily represent those of Nasdaq, Inc.

[object Object]
Preview
9.5
08-13NASDAQ.COM
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

  • Earnings Performance: Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the expected loss of $0.64, marking a 29.69% earnings surprise; however, revenues of $0.59 million fell short of estimates by 7.81%.

  • Market Outlook: The company's stock has underperformed with a 30.8% decline this year, and its future performance will depend on management's commentary and revisions to earnings estimates, currently rated as Zacks Rank #3 (Hold).

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CASI Pharmaceuticals Inc (CASI) stock price today?

The current price of CASI is 0.9783 USD — it has increased 4.04 % in the last trading day.

arrow icon

What is CASI Pharmaceuticals Inc (CASI)'s business?

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

arrow icon

What is the price predicton of CASI Stock?

Wall Street analysts forecast CASI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CASI is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CASI Pharmaceuticals Inc (CASI)'s revenue for the last quarter?

CASI Pharmaceuticals Inc revenue for the last quarter amounts to 3.08M USD, decreased -60.54 % YoY.

arrow icon

What is CASI Pharmaceuticals Inc (CASI)'s earnings per share (EPS) for the last quarter?

CASI Pharmaceuticals Inc. EPS for the last quarter amounts to -0.68 USD, increased 23.64 % YoY.

arrow icon

What changes have occurred in the market's expectations for CASI Pharmaceuticals Inc (CASI)'s fundamentals?

The market is revising No Change the revenue expectations for CASI Pharmaceuticals, Inc. (CASI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -58.19%.
arrow icon

How many employees does CASI Pharmaceuticals Inc (CASI). have?

CASI Pharmaceuticals Inc (CASI) has 233 emplpoyees as of December 05 2025.

arrow icon

What is CASI Pharmaceuticals Inc (CASI) market cap?

Today CASI has the market capitalization of 20.10M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free